Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TPST 1495

Next Previous
Search
Drug Profile

TPST 1495

Alternative Names: TPST-1495

Latest Information Update: 18 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tempest Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Prostaglandin E EP2 receptor antagonists; Prostaglandin E EP4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 09 Apr 2025 TPST 1495 receives Orphan Drug status for Familial adenomatous polyposis in USA
  • 13 Mar 2025 The Cancer Prevention Clinical Trials Network receives a “Study May Proceed” letter from the US Food and Drug Administration (FDA) for phase II trial for Familial adenomatous polyposis (FAP)
  • 13 Mar 2025 Tempest Therapeutics in collaboration with NCI plans a phase-II trial for Familial adenomatous polyposis in Puerto Rico and USA (PO) in 2025 (NCT06557733)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top